Canine immune-mediated polyarthritis (IMPA) is a diagnosis of exclusion based predominantly on clinical signs, characteristic joint fluid analysis, and elimination of potential joint infection. Ultimately, an appropriate and sustained response to immunosuppressive therapy may become the final diagnostic criterion used. Identifying associated disease processes, including breed-specific syndromes, remote infection, inflammation, drug exposure, vaccine exposure, or neoplasia, as well as initial response to therapy, is often an important contributor to prognosis. This review article is the second of a two part series and focuses on the diagnosis and treatment of immune-mediated polyarthritis. The first article in this series, published in the January/February 2012 issue, concentrated on the pathophysiology of IMPA.
Introduction
Immune-medicated polyarthritis (IMPA) is an important disease process in the dog. Inflammation in multiple joints can lead to intense pain and may profoundly affect quality of life. This review article is the second of a two part series. It's aim is to concentrate on the diagnosis and treatment of immune-medicated polyarthritis.
Epidemiology
Most retrospective studies of dogs with nonerosive immunemediated polyarthritis report no sex predilection for the condition and report that young to middle-aged, medium-to large-breed dogs are most commonly affected. [1] [2] [3] [4] Retrievers, spaniels, and German Shepherd dogs are strongly represented. [1] [2] [3] [4] [5] [6] Although one study looking specifically at type I IMPA diagnosed a high incidence of affected German Shepherd dogs and Labrador retrievers, statistical analysis revealed that neither breed had an increased risk compared with the general hospital population. 2 Another retrospective study of 40 dogs with nonerosive polyarthritis reported the cocker spaniel to be at increased risk and found that small-to medium-breed female dogs were over-represented. 5 Finally, a recent study describing IMPA in a population of dogs from western Canada, where tick-borne disease is uncommon, found that middle-aged to older dogs weighing ,10 kg were most commonly affected, suggesting that American Eskimos and Labrador retrievers may be predisposed to idiopathic IMPA. 6 These varied findings from different case series reinforce the fact that clinicians should consider IMPA to be a reasonable diagnostic possibility in dogs of any sex, age, breed, or size.
Major Presenting Complaints and Clinical Signs
IMPA can cause nonspecific systemic signs such as weight loss, inappetence, lethargy, and reluctance to move. Owners may or may not report more specific clinical signs such as swollen joints, altered gait, or lameness. Vomiting and diarrhea may also be mentioned in the recent history. 4, 6 Various retrospective studies of dogs with IMPA have found a range of clinical signs, although most reported fever, lethargy, weakness, reluctance to walk, a stiff or stilted gait, lameness, swelling of multiple joints (often in a bilaterally symmetrical pattern), and pain on palpation of the joints. [2] [3] [4] [5] [6] Neck and back pain may also be present either if vertebral articular facets are involved or if meningitis is present. 3 Clinicians should be aware that dogs with IMPA commonly present with no obvious joint swelling or localizable pain. In one study of 40 dogs with polyarthritis, only 35% demonstrated lameness and only 40% demonstrated joint swelling. 5 In addition,
IMPA has been reported as one of the most common causes of fever of unknown origin in dogs. 7 
Diagnostics and Differential Diagnoses
Ultimately, IMPA is diagnosed by arthrocentesis and synovial fluid analysis. Further diagnostic testing is necessary to determine whether an underlying disease is causing a reactive polyarthritis. In addition, other causes of joint disease, including septic arthritis, degenerative joint disease, neoplastic arthropathy, trauma, and hemophilic arthropathy, should be ruled out. Most of these listed conditions, however, are more likely to affect a single joint rather than the multiple joints typically affected in dogs with IMPA. 1 When evaluating a dog with suspected polyarthritis, a recommended minimum database should include a complete blood count (CBC), serum chemistry panel, urinalysis, and urine culture. 1 Common CBC and blood chemistry findings noted in dogs with IMPA include leukocytosis, mild nonregenerative anemia, and mild hypoalbuminemia. A mild to moderate elevation in serum alkaline phosphatase (of an as yet undetermined cause) is also common. [2] [3] [4] [5] [6] A positive urine culture can help identify a urinary or blood-borne bacterial infection.
A thorough search for evidence of underlying infection, inflammatory disease, or neoplasia should be undertaken, including thoracic and abdominal radiographs and abdominal ultrasonography. If back or neck pain is detected, radiographs of the spine are indicated. In addition, radiographs of multiple joints should be considered to look for evidence of synovial effusion, soft tissue swelling, and signs of joint erosion and destruction, and to rule out other possible causes of joint disease. The hocks, carpi, and stifles are the most commonly affected joints in dogs with IMPA, whereas the more proximal and larger joints are more likely to be involved in patients with infectious arthritis. tained from smear evaluation alone were often falsely elevated and that there was considerable variation in estimated cell counts between clinicians. 27 A synovial fluid smear can, however, be used to estimate the total nucleated cell count into broad categories of normal, increased, or markedly increased.
14 Normal canine synovial fluid contains ,3,000 cells/mL.
14 Greater than 90% of these cells are mononuclear and ,5% are mature, nondegenerate neutrophils. 15 The majority of mononuclear cells are nonreactive macrophages with few vacuoles.
Small lymphocytes are also present in lower numbers and, on occasion, a synoviocyte may be seen. 15 In canine IMPA, synovial fluid volume is often increased. Fluid obtained may be turbid and/or discolored, and it typically has a decreased viscosity. The protein and nucleated cell content are usually increased, with cell 14 One canine study demonstrated that inoculating a pediatric blood culture bottle with synovial fluid, incubating for at least 24 hr, and then streaking the blood culture medium on appropriate plate media significantly reduced false negative culture results. This approach was also more successful than synovial membrane biopsy cultures. 28 Joint fluid collected in EDTA should not be cultured because the anticoagulant can inhibit bacterial growth.
More recently, real-time broad-based polymerase chain reaction assays have been described that rapidly identify bacteria in synovial fluid. These methodologies may eventually replace joint fluid culture as a means of identifying joint infection in dogs. [29] [30] [31] Infectious agents are occasionally identified by direct cytologic examination of joint fluid. For example, rickettsial morulae have been found in neutrophils in the synovial fluid of up to 1% of affected patients. 15 Other organisms that may be seen include bacteria within neutrophils, B. burgdorferi spirochetes, Mycoplasma spp., Leishmania amastigotes within macrophages, and either fungal hyphae or yeast bodies. Juvenile-onset polyarthritis in Akitas has also been treated with multidrug protocols, including a combination of prednisone and azathioprine, but with a less reliable positive outcome. 39 In dogs with type II-IV idiopathic polyarthritis, joint inflammation will usually resolve when the underlying disease process is successfully
Canine Immune-Mediated Polyarthritis identified and either treated or removed. Occasionally, additional treatment with analgesics and possibly glucocorticoids will be required. [21] [22] [23] Again, in many cases of type II (reactive) polyarthritis triggered by infection, immunosuppressive doses of steroids will be contraindicated. 40 Tick-borne diseases, however, may benefit from concurrent treatment with doxycycline and a tapering dose of glucocorticoids. [41] [42] [43] [44] Sulfasalazine has been used to treat cases of type III (enteropathic) arthritis and rheumatoid arthritis associated with gastrointestinal disease and provides a combination of antibacterial, anti-inflammatory, and immunosuppressive properties. 40 Side effects of this medication are uncommon but can be severe as described in Table 1 .
Once no underlying cause of polyarthritis has been identified, infection has been reasonably excluded, and a provisional diagnoses of type I (uncomplicated) idiopathic polyarthritis has been established, a tapering dose of a glucocorticoid is indicated if symptoms persist after more conservative treatment protocols have failed.
Immunosuppressive doses of prednisone, prednisolone, or methylprednisone (2-3 mg/kg/day q 24 hr or divided) can be started initially. This dose is administered until there is no cytologic Rheumatoid arthritis, IMPA
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Mycophenolate mofetil
Inhibits T and B cell proliferation during S phase 10 mg/kg PO q 8hr or 10 mg/kg PO q 12 hr.
Monitor for hemorrhagic GI side effects, weight loss, decreased activity, lymphopenia, and infection. 33 
Rheumatoid arthritis
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Taper dose by 50% after 2-3 wk or if hemorrhagic GI signs are noted 69, 70 Mycophenolate mofetil capsules may produces less side effects than sodium salt enteric-coated tablets 33 
Levamisole
Anthelmintic with immunomodulatory action
Combine 0. 45 In a recent prospective study, 14 dogs received leflunomide as the primary treatment of IMPA.
Other medications given concurrently in some dogs in that study included NSAIDs, tramadol, and doxycycline. Of the 14 dogs, 1 dog did not respond, 5 dogs had a partial response, and 8 dogs returned
to a normal quality of life based on subjective assessment of clinical signs. 45 Leflunomide side effects were minimal and most dogs were treated for 4-6 wk before a dose reduction was attempted. 45 When treating with a combination protocol, once remission of clinic signs is achieved, the drug causing the most concerning side effects (or, if no major side effects are seen, the most expensive drug) is typically tapered first. There are no controlled studies in dogs that show that one immunosuppressive agent is better than another for treatment of IMPA, and efficacy seems to depend on the individual patient. 2, 4, 23 Therefore, if one immunosuppressive agent does not appear to be working, it can be replaced by another. In some patients, all drug therapy can gradually be tapered then discontinued without relapse. In other patients, an ongoing, low dose of a glucocorticoid is required in conjunction with an immunosuppressive agent. In these cases, the lowest possible doses that maintain clinical remission should be administered. 40 Controlling pain is also an important part of restoring quality of life and allowing for tapering of immunosuppressive medications. Oral analgesics that may be combined with either NSAIDs or corticosteroids to control pain include tramadol, gabapentin, amantadine, and acetaminophen. 45, 46 49 One study of SLE dogs described a protocol that combined prednisone at E and selenium, curcumin with bioperine, a-lipoic acid, boswellia, resveratrol, and lecithin. 51, 52 The use of NSAIDs, such as dipyrone or meloxicam, has been described to control fever in dogs with temperatures .40.6 8 C. 51, 52 Colchicine is administered to impair the release of serum amyloid A from the liver by binding to hepatocyte microtubules and preventing amyloid secretion. Chronic administration of colchicine should be paired with cobalamin supplementation (Table 2) . 51, 52 Erosive arthritis in dogs is more refractory to treatment and may require life-long therapy. 53 Because Mycoplasma spp. have been found in the joints of some greyhounds with erosive arthritis, trial therapy using an antibiotic effective against these organisms (such as tylosin) may be warranted before considering immunosuppressive therapy. 40, 53 There is little published data available regarding the treatment of rheumatoid arthritis in dogs. cyclosporine, and leflunomide. Chrysotherapy using gold salts has also been recommended for refractory cases of canine rheumatoid arthritis. 23, 40 Human patients who fail to respond to standard DMARDs may be prescribed tumor necrosis factor 54, 55 Alternatives to TNF-a blocking agents in human rheumatoid arthritis patients include the interleukin-1 receptor antagonist anakinra, the T cell costimulation modulator abatacept, and the B cell modulator rituximab. 54 The essential protein structure and properties of both TNF-a and interleukin-1 are highly conserved among mammals.
It is therefore possible that dogs with rheumatoid arthritis and conceivably other forms of IMPA could eventually be shown to benefit from medications developed for use in humans that target these particular cytokines. 57 In addition to immunosuppressive drug therapy, splenectomy is the last resort treatment for Felty's syndrome (rheumatoid arthritis, neutropenia, and splenomegaly). 23, 58 Splenectomy is based on the presumption that the spleen is the site of immune-mediated neutrophil destruction. high in omega-3 fatty acids should also be considered in an effort to control inflammation. 40, 59 In dogs with apparently nonerosive IMPA that is refractory to therapy, periodic radiographs of multiple joints are warranted to look for progression to erosive arthritis. 63 Currently, a commercial enzyme-linked immunosorbent assay kit is available that is specific for canine CRP. 64 
Prognosis
Erosive arthritis in dogs is associated with a poor long-term prognosis. In most cases, multidrug protocols are required to keep the disease in remission. Permanent joint destruction often leads to an inferior quality of life, even if the underlying inflammatory process responds to medical therapy. 23, 53 In contrast, the prognosis for most forms of nonerosive polyarthritis in dogs is fair to good. The prognosis in dogs with idiopathic polyarthritis depends on the subtype. In dogs with types II-IV, the prognosis is good and relapse is unlikely if the underlying disease can be identified and resolved. [21] [22] [23] Outcomes in dogs with type I (uncomplicated) idiopathic polyarthritis are also generally favorable. One study of 39 cases of canine type I polyarthritis reported that most responded to therapy: 56% of affected dogs were cured, 13% relapsed but were subsequently treated successfully, 18% required life-long therapy to maintain remission, and only 15% were euthanized or died because of their disease. 2 Relapses occurred weeks to months after tapering or stopping medications. 2 Some of the dogs that relapsed required life-long therapy to remain in remission, whereas others were finally cured. 2 When clinical signs resolved, remission was confirmed via repeat synovial fluid analysis. 2 The prognosis for dogs with vaccine-and drug-induced IMPA is excellent. Recovery times are usually relatively short, and relapse is unlikely. 40, 65 Akitas with vaccine-induced IMPA, however, are reported to require more intense initial therapy compared with most other dog breeds and are less likely to respond to treatment. 65, 66 A case report describing spaniels with polyarthritis/polymyositis suggested that this condition can be challenging to treat. Only two of six dogs achieved complete remission during treatment with a combination of cyclophosphamide and prednisone. Of the remaining four dogs, two relapsed and two never responded to therapy. 36 
